Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London.
33 - 37
J Clin Virol
MetadataShow full item record
BACKGROUND: Hepatitis delta virus (HDV) testing is recommended for all patients with hepatitis B virus (HBV) infection. HDV infection is associated with severe liver disease and interferon is the only available treatment. OBJECTIVES: To determine the rate of anti-HDV antibody testing in HBV patients; and to describe the epidemiology, clinical characteristics and management of HDV-infected patients at four hospitals in London. STUDY DESIGN: The anti-HDV testing rate was estimated by reviewing clinical and laboratory data. Cross-sectional data collection identified HDV-infected patients who had attended the study centres between 2005 and 2012. RESULTS: At a centre with clinic-led anti-HDV testing, 40% (67/168) of HBV patients were tested. Recently diagnosed HBV patients were more likely to be screened than those under long-term follow-up (62% vs 36%, P=0.01). At a centre with reflex laboratory testing, 99.4% (3543/3563) of first hepatitis B surface antigen positive samples were tested for anti-HDV. Across the four study centres there were 55 HDV-infected patients, of whom 50 (91%) had immigrated to the UK and 27 (49%) had evidence of cirrhosis. 31 patients received interferon therapy for HDV with an end of treatment virological response observed in 10 (32%). CONCLUSIONS: The anti-HDV testing rate was low in a centre with clinic-led testing, but could not be evaluated in all centres. The HDV-infected patients were of diverse ethnicity, with extensive histological evidence of liver disease and poor therapeutic responses. Future recommendations include reflex laboratory testing algorithms and a prospective cohort study to optimise the investigation and management of these patients.
AuthorsEl Bouzidi, K; Elamin, W; Kranzer, K; Irish, DN; Ferns, B; Kennedy, P; Rosenberg, W; Dusheiko, G; Sabin, CA; Smith, BC; Nastouli, E
- Immune Systems 
Showing items related by title, author, creator and subject.
High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B Hansi, NK; Gill, US; Banerjee, A; Surendraraj, N; Patel, C; Naik, S; Foster, GR; Kennedy, PT (2014)
Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. Crespo, M; Navarro, J; Moreno, S; Sanz, J; Márquez, M; Zamora, J; Ocampo, A; Iribaren, JA; Rivero, A; Llibre, JM (2016-04-06)INTRODUCTION: Limited data is available regarding the hepatic safety of maraviroc in patients co-infected with HIV and HCV and/or HBV. Our objective was to compare the hepatic safety profile and fibrosis progression in ...
Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified. Foster, GR; Gore, C; Hudson, M; Moss, P; Ustianowski, A; Ryder, S; Bhagani, S (2015)